CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 61 enrolled
Drug / intervention
Aristadrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05522153
NCT05522153Phase 1Completed
CompareCT.gov

A Single Blinded Randomized Control Trial Comparing the Use of ARISTA Polysaccharide Hemostat in Total Knee Arthroplasty (TKA)

Virtua Health, Inc.·interventional·Posted Aug 30, 2022·Updated Sep 19, 2024

In Brief

A Phase 1 clinical trial evaluating Arista for Blood Loss, Surgical. Completed, enrolled 61 participants across 1 site.

Detailed Summary

To examine in Arista hemostatic powder results in less post-total knee arthroplasty blood loss, hematoma formation, and improved range of motion when compared to patients who did not receive the product.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBlood Loss, Surgical
CountriesUnited States
CollaboratorsBecton, Dickinson and Company

Timeline

Phase 1CompletedFinished
20222023202420252026
First PostedAug 30, 2022
Enrollment StartMay 1, 2021
Primary CompletionJun 8, 2023
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 3.8 years ago

Interventions

Aristadrug

hemostatic powder